| 000 | 01714 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517235228.0 | ||
| 264 | 0 | _c20181217 | |
| 008 | 201812s 0 0 eng d | ||
| 022 | _a1471-2474 | ||
| 024 | 7 |
_a10.1186/s12891-018-2215-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLu, Xin | |
| 245 | 0 | 0 |
_aLow molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis. _h[electronic resource] |
| 260 |
_bBMC musculoskeletal disorders _cSep 2018 |
||
| 300 |
_a322 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Systematic Review | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnticoagulants _xadverse effects |
| 650 | 0 | 4 |
_aAntithrombins _xtherapeutic use |
| 650 | 0 | 4 |
_aArthroplasty, Replacement, Hip _xadverse effects |
| 650 | 0 | 4 |
_aArthroplasty, Replacement, Knee _xadverse effects |
| 650 | 0 | 4 |
_aFactor Xa Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFibrinolytic Agents _xadverse effects |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 |
_aHeparin, Low-Molecular-Weight _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPulmonary Embolism _xdiagnosis |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVenous Thromboembolism _xdiagnosis |
| 650 | 0 | 4 |
_aVenous Thrombosis _xdiagnosis |
| 700 | 1 | _aLin, Jin | |
| 773 | 0 |
_tBMC musculoskeletal disorders _gvol. 19 _gno. 1 _gp. 322 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12891-018-2215-3 _zAvailable from publisher's website |
| 999 |
_c28814235 _d28814235 |
||